Developing a vaccine to prevent diseases caused by the Human T Cell Lymphotropic Virus
Human T Cell Lymphotropic Virus Vaccine Development
This study is testing a new vaccine to help prevent and treat serious health issues linked to the HTLV-1 virus, like adult T cell leukemia and a nerve condition called HAM/TSP, and it's for people who might be at risk of getting this virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stinginn, LLC NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project ID | NIH-10821613 on NIH RePORTER |
What this research studies
This research focuses on creating a novel immunotherapeutic vaccine aimed at preventing and treating diseases associated with the Human T Cell Lymphotropic Virus type-1 (HTLV-1), particularly adult T cell leukemia/lymphoma (ATLL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). The approach involves evaluating the safety and efficacy of this vaccine in individuals who may be at risk of HTLV-1 infection. Given the high prevalence of HTLV-1 in certain regions, the study aims to provide a much-needed preventive measure against these serious health conditions. Patients participating in this research may receive the vaccine and be monitored for its effects on their health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of HTLV-1 infection, particularly those living in endemic regions or with a family history of HTLV-1 associated diseases.
Not a fit: Patients who are not at risk of HTLV-1 infection or those who have already developed HTLV-1 associated diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective vaccine that prevents serious diseases caused by HTLV-1, significantly improving patient outcomes.
How similar studies have performed: While this approach is novel in the context of HTLV-1, similar immunotherapeutic vaccine strategies have shown promise in other viral infections, indicating potential for success.
Where this research is happening
Miami, United States
- Stinginn, LLC — Miami, United States (Active)
Researchers
- Principal investigator: Barber, Glen N — Stinginn, LLC
- Study coordinator: Barber, Glen N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.